Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab Extension in Hypereosinophilic Syndromes
NCT00097370Phase 3Terminated
- Sponsor
- GSK
- Start
- Sep 2004
- Primary completion
- Sep 2010
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in hypereosinophilic syndrome (HES), sponsored by GSK. Primary endpoints: Number of Participants With Any Adverse Event (AE) During the Treatment Phase up to 6 years and Number of Participants With Any Adverse Event (AE) During the Follow-up Phase up to 6 years. Started Sep 2004; status: terminated.
02
Drugs
mepolizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NCT00097370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00097370.